Sex-specific clinical characteristics and prognosis of coronavirus disease-19 infection in Wuhan, China: A retrospective study of 168 severe patients.
Journal
PLoS pathogens
ISSN: 1553-7374
Titre abrégé: PLoS Pathog
Pays: United States
ID NLM: 101238921
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
01
03
2020
accepted:
06
04
2020
revised:
08
05
2020
pubmed:
29
4
2020
medline:
14
5
2020
entrez:
29
4
2020
Statut:
epublish
Résumé
To confirm the relationship between sex and the progression of Coronavirus Disease-19 (COVID-19), and its potential mechanism, among severe patients. For this retrospective study, we included 168 consecutive severe patients with pathogen-confirmed COVID-19 who were hospitalized between January 16th and February 4th, 2020, at Tongji Hospital in Wuhan, China. Clinical characteristics, laboratory parameters, and outcomes were compared and analyzed between males and females. In the present study, we analyzed 168 severe patients with COVID-19, including 86 males and 82 females, and 48 patients (28.6%) were diagnosed as critically ill. Of 86 male patients, 12.8% (11/86) died and 75.6% (65/86) were discharged; of 82 female patients, 7.3% (6/82) died and 86.6% (71/82) were discharged. Eleven laboratory parameters showed significant differences between male and female patients, and six of them were higher during the whole clinical course in patients who died than in patients who were discharged. In adjusted logistic regression analysis, males with comorbidities presented a higher risk of being critically ill than males without comorbidities (OR = 3.824, 95% CI = 1.279-11.435). However, this association attenuated to null in female patients (OR = 2.992, 95% CI = 0.937-9.558). A similar sex-specific trend was observed in the relation between age and critically ill conditions. We highlighted sex-specific differences in clinical characteristics and prognosis. Male patients appeared to be more susceptible to age and comorbidities. Sex is an important biological variable that should be considered in the prevention and treatment of COVID-19.
Identifiants
pubmed: 32343745
doi: 10.1371/journal.ppat.1008520
pii: PPATHOGENS-D-20-00413
pmc: PMC7209966
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1008520Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Lancet. 2020 Feb 22;395(10224):565-574
pubmed: 32007145
Lancet. 2020 Mar 7;395(10226):760-762
pubmed: 32151334
J Immunol. 2017 May 15;198(10):4046-4053
pubmed: 28373583
Nat Rev Immunol. 2016 Oct;16(10):626-38
pubmed: 27546235
Int J Infect Dis. 2016 Aug;49:129-33
pubmed: 27352628
JAMA. 2020 Feb 7;:
pubmed: 32031570
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632
Nature. 2020 Mar;579(7798):265-269
pubmed: 32015508
Bioessays. 2011 Nov;33(11):791-802
pubmed: 21953569
N Engl J Med. 2020 Mar 26;382(13):1199-1207
pubmed: 31995857
Allergy. 2020 Feb 19;:
pubmed: 32077115
EBioMedicine. 2020 Apr 18;55:102763
pubmed: 32361250
Exp Physiol. 2008 May;93(5):658-64
pubmed: 18192335
Lancet. 2020 Mar 7;395(10226):809-815
pubmed: 32151335
PLoS Pathog. 2011 Jul;7(7):e1002149
pubmed: 21829352
Am J Epidemiol. 2004 Feb 1;159(3):229-31
pubmed: 14742282